Fremanezumab
Based on 2 publication(s) in Google Scholar
Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC50 values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC50 value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 95.00%
- CAS. Nr.: 1655501-53-3
- Molecular Weight:145.5 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Fremanezumab
More
Biologische Aktivität
Human IgG2 kappa
Human
CALCA/CGRP
Fremanezumab (10 μM, 6 h) counteracts the concentration-dependent inhibitory effects of mouse CGRP on LPS (HY-D1056)-induced increases in IL1β, IL6, and IL12 transcripts in primary cultures of C57Bl mouse microglia, but does not alter microglia activation alone upon LPS incubation[1].
Fremanezumab (72 h) prevents the concentration-dependent inhibition of proliferation of splenocytes derived from day 30 MOG35-55-immunized NOD by mouse CGRP, but does not alter lymphocyte proliferation alone[1].
Fremanezumab (1-100 ng, 1 h) reduces immunodetection of human and mouse CGRP with IC50s of 7.94 nM and 19.6 nM, respectively[1].
Fremanezumab ((0.00001-1 μM) significantly inhibits the vasodilatory effects induced by human αCGRP, rat αCGRP and the metabolically stable CGRP analog SAX in rat cerebral basilar artery segments and reduces the potency of CGRP (pEC50 from 8.0 to 6.3) and SAX (pEC50 from 7.2 to 6.2)[2]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Fremanezumab (30 mg/kg, i.v., once) selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in anesthetized male rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats (225-325 g)[3]
-
Dosage:30 mg/kg
-
Administration:i.v., once
-
Result:Achieved a significantly lower activation rate of Aδ meningeal nociceptors by CSD.
Showed a significant increase in the firing rate of activated C-fiber meningeal nociceptors.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 A549 cells with Fremanezumab (HY-P99019, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa (HY-P99002, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS. Nr. 1655501-53-3
-
Appearance Liquid
-
Molecular Weight 145.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Fremanezumab]
-
Synonyms
TEV-48125; LBR-101; PF-04427429; RN-307
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
PVNCRF Neurons Regulate Migraine-Like Allodynia by Activating CRFR2 on Spinal Trigeminal Caudalis Glutamatergic Neurons. [Abstract]2026 Feb 28:e20530. PMID: 41762709 -
Biosens Bioelectron
One-step ultra-rapid immunoassay of calcitonin gene-related peptide for migraine diagnosis. [Abstract]2025 Feb 15:270:116980. PMID: 39608279
Reinheit & Dokumentation
-
Data Sheet (263 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Pistolesi A, et al. The anti-CGRP mAb Fremanezumab reverts the anti-inflammatory effects of CGRP in vitro but does not alter disease evolution in a mouse model of progressive multiple sclerosis. Eur J Pharmacol. 2025 May 15;995:177415. [Content Brief]
[2]. Grell AS, et al. Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction. Eur J Pharmacol. 2019 Dec 1;864:172726. [Content Brief]
[3]. Melo-Carrillo A, et al. Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors. J Neurosci. 2017 Nov 1;37(44):10587-10596. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Fremanezumab Related Classifications
HY-P99019 Related Classifications
Powered by Bioz